The development and use of small molecule inhibitors of glycosphingolipid metabolism for lysosomal storage diseases
Glycosphingolipid (GSL) storage diseases have been the focus of efforts to develop small molecule therapeutics from design, experimental proof of concept studies, and clinical trials. Two primary alternative strategies that have been pursued include pharmacological chaperones and GSL synthase inhibi...
Main Authors: | James A. Shayman, Scott D. Larsen |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2014-07-01
|
Series: | Journal of Lipid Research |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0022227520352305 |
Similar Items
-
Mechanistic Insights into the Chaperoning of Human Lysosomal-Galactosidase Activity: Highly Functionalized Aminocyclopentanes and <i>C</i>-5a-Substituted Derivatives of 4-<i>epi</i>-Isofagomine
by: Patrick Weber, et al.
Published: (2020-09-01) -
Property-based design of a glucosylceramide synthase inhibitor that reduces glucosylceramide in the brain
by: Scott D. Larsen, et al.
Published: (2012-02-01) -
Glycosphingolipids and Infection. Potential New Therapeutic Avenues
by: Johannes M. F. G. Aerts, et al.
Published: (2019-12-01) -
Profile of eliglustat tartrate in the management of Gaucher disease
by: Sechi A, et al.
Published: (2016-01-01) -
Lysosomal Proteomics Links Disturbances in Lipid Homeostasis and Sphingolipid Metabolism to CLN5 Disease
by: Stefano Doccini, et al.
Published: (2022-06-01)